Industry News (Therapy)

FDA Market Clearance for Doxil Received

Published in Cancer Weekly, December 4th, 1995

Sequus Pharmaceuticals, Inc., Menlo Park, California, announced the receipt of U.S. Food and Drug Administration (FDA) market clearance for doxorubicin HCl liposome injection (Doxil).

Doxil is indicated for the treatment of Kaposi's sarcoma (KS) in people with AIDS whose KS disease has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. Doxil is a Stealth liposome formulation of doxorubicin, an off-patent anticancer drug.

"FDA market clearance of Doxil is a significant milestone for patients with Kaposi's sarcoma," said Chairman and Chief Executive Officer, Dr. I. Craig Henderson. "Doxil is a new...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-12-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry